Details for Patent: 8,741,963

Title:	S1P receptor modulators for treating multiple sclerosis
Abstract:	The present invention relates to the use of the S1P receptor modulator 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, administered at a daily dosage of 0.5 mg, for inhibiting or treating neo-angiogenesis associated with multiple sclerosis.
Inventor(s):	Hiestand; Peter C. (Allschwil, CH), Schnell; Christian (Hesingue, FR)
Assignee:	Novartis AG (Basel, CH)
Filing Date:	May 31, 2011
Application Number:	13/149,468
Claims:	1. A method for inhibiting or treating neo-angiogenesis associated with multiple sclerosis in a subject in need thereof, comprising administering to said subject 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, in free form or in a pharmaceutically acceptable salt form, at a daily dosage of 0.5 mg, absent an immediately preceding loading dose regimen. 2. A method according to claim 1, wherein said multiple sclerosis is primary progressive multiple sclerosis. 3. A method according to claim 1 wherein 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride is administered. 4. A method according to claim 3, wherein said multiple sclerosis is primary-progressive multiple sclerosis. 5. A method according to claim 2, wherein 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride is administered. 6. A method according to claim 1, wherein said multiple sclerosis is relapsing-remitting multiple sclerosis. 7. A method for reducing or alleviating relapses in primary progressive multiple sclerosis in a subject in need thereof, comprising administering to said subject 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, in free form or in a pharmaceutically acceptable salt form, at a daily dosage of 0.5 mg, absent an immediately preceding loading dose regimen. 8. A method according to claim 7, wherein 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride is administered. 9. A method for slowing progression of multiple sclerosis in a subject in the relapsing-remitting phase of primary progressive multiple sclerosis, comprising administering to said subject 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, in free form or in a pharmaceutically acceptable salt form, at a daily dosage of 0.5 mg, absent an immediately preceding loading dose regimen.